Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Jakafi
Pharma
Incyte reports Opzelura sales up 33% in 2025, plots '26 growth
In its fourth full year on the market, Incyte's Opzelura generated sales of $678 million, which were up 33% increase from 2024.
Kevin Dunleavy
Feb 10, 2026 11:48am
New Incyte CEO takes 'fresh look' at business, outlines BD plan
Aug 4, 2025 11:16am
Incyte, Novartis reach settlement in Jakafi royalty dispute
May 6, 2025 10:15am
Sun Pharma beats Incyte in appeals, teeing up US alopecia launch
Apr 10, 2025 10:00am
Incyte provides first guidance for JAK cream Opzelura
Feb 10, 2025 2:25pm
JPM25: Incyte plans to turn 'a lot of cards' in 2025, CEO says
Jan 22, 2025 2:38pm
